Ask what is BPC-157 and you'll hear it has 30 years of research behind it. The 30 years part is true. So most people figure it's been well tested in people by now. It hasn't.
What is BPC-157? A small piece, studied mostly in rats
BPC-157 is a chain of 15 amino acids. Think beads on a string. The name stands for "body protection compound," and it comes from a group at the University of Zagreb in Croatia. In a 1993 paper they described BPC, a much bigger protein isolated from gastric juice, and this 15-bead piece, the part they thought did the work. Three decades later, nearly all of what's known about it comes from animals and cells.
The proof: one lab, a lot of rats, a handful of people
Let's get into it.
It's a tiny piece of a much bigger protein. The 1993 paper put the parent protein, BPC, at a molecular weight of about 40,000 (Sikirić et al., J Physiol Paris 1993). BPC-157 weighs about 1,420. Picture a 28-page booklet and tearing out one page. That one page is BPC-157.
Most of the research comes from that same lab. Search PubMed for BPC 157 in October 2026 and you get 231 records. Predrag Sikirić, the Zagreb pharmacologist who was first author on that 1993 paper, is an author on 175 of them. That's about three in four. One group doing most of the work isn't a red flag by itself. It just means fewer independent labs have checked the results.
The human record fits on an index card. When FDA reviewers searched the medical literature for a July 2026 advisory meeting, they found five human studies (FDA briefing document, 2026). Two were early 2000s trials from Pliva, a Croatian drug company, published only as conference abstracts. The other three came from Florida clinics, with the same lead author each time. They had 17, 12 and 2 people. None had a comparison group. A larger, placebo-controlled trial registered in 2026 is still recruiting, with no results yet (ClinicalTrials.gov NCT07437547).
Regulators haven't settled it either. On July 23, 2026, an FDA advisory panel voted 8 to 6, with one abstention, to recommend BPC-157 for the pharmacy compounding list. FDA's own reviewers had recommended against it. That vote is non-binding, and as of October 2026 the FDA hasn't acted. Sports are simpler. WADA names BPC-157 on its 2026 Prohibited List, banned at all times (WADA 2026 List).
So why should you care? None of that history tells you what's in a vial. The certificate does. PubChem lists BPC-157 at a molecular weight of 1,419.5 (PubChem CID 9941957). The LC-MS identity result on a certificate of analysis, or COA, should match that mass, give or take a fraction. If it doesn't, you're holding something else.
"Is BPC-157 acetate a different compound?" Nope. The FDA review treats the free base and the acetate as two forms of the same active part, BPC-157. Same 15-bead chain.
The big learning lesson
Keep reading: Why BPC-157 and TB-500 are studied together · The FDA "peptide ban" of 2026, explained · How to read a peptide COA
Frequently asked questions
What is BPC-157 made of?
Fifteen amino acids in a fixed order: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. PubChem lists its formula as C62H98N16O22 and its molecular weight as 1,419.5.
Where does BPC-157 come from?
It's a fragment of BPC, short for body protection compound, a larger protein a University of Zagreb team described in gastric juice in the early 1990s. BPC-157 is the 15-amino-acid piece they thought was essential to its activity.
Is BPC-157 FDA approved?
No. An FDA advisory panel recommended it for the pharmacy compounding list in July 2026, but that vote isn't binding and isn't an approval. WADA also lists it as prohibited at all times.